KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZN) Receivables (2016 - 2025)

Astrazeneca has reported Receivables over the past 11 years, most recently at $17.2 billion for Q4 2025.

  • Quarterly results put Receivables at $17.2 billion for Q4 2025, up 18.16% from a year ago — trailing twelve months through Dec 2025 was $17.2 billion (up 18.16% YoY), and the annual figure for FY2025 was $17.2 billion, up 18.16%.
  • Receivables for Q4 2025 was $17.2 billion at Astrazeneca, up from $14.6 billion in the prior quarter.
  • Over the last five years, Receivables for AZN hit a ceiling of $17.2 billion in Q4 2025 and a floor of $8.9 billion in Q4 2022.
  • Median Receivables over the past 5 years was $11.5 billion (2021), compared with a mean of $12.4 billion.
  • Biggest five-year swings in Receivables: decreased 22.54% in 2022 and later soared 44.84% in 2024.
  • Astrazeneca's Receivables stood at $11.5 billion in 2021, then decreased by 22.54% to $8.9 billion in 2022, then grew by 13.25% to $10.0 billion in 2023, then soared by 44.84% to $14.6 billion in 2024, then rose by 18.16% to $17.2 billion in 2025.
  • The last three reported values for Receivables were $17.2 billion (Q4 2025), $14.6 billion (Q4 2024), and $10.0 billion (Q4 2023) per Business Quant data.